{"disease":{"id":"sars","name":"sars"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04958954","title":"Post-Marketing Safety Study of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in the United States","phase":"","overall_status":"COMPLETED","enrollment_count":50000000,"lead_sponsor_name":"ModernaTX, Inc.","has_results":false},{"nct_id":"NCT06199934","title":"Effectiveness of BNT162b2 Formulations Using State Vaccine Registry and Insurance Claims Data","phase":"","overall_status":"COMPLETED","enrollment_count":19853610,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT06130345","title":"Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran","phase":"","overall_status":"COMPLETED","enrollment_count":15196685,"lead_sponsor_name":"ModernaTX, Inc.","has_results":false},{"nct_id":"NCT04738331","title":"Analysing the French COVID-19 Epidemic Using a National SARS-CoV-2 RT-PCR Database","phase":"","overall_status":"UNKNOWN","enrollment_count":10000000,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT04653844","title":"RT-PCR Database Analysis for COVID-19 Infections and Re-infection","phase":"","overall_status":"UNKNOWN","enrollment_count":7000000,"lead_sponsor_name":"University Hospital, Montpellier","has_results":false},{"nct_id":"NCT05020145","title":"COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United States","phase":"","overall_status":"COMPLETED","enrollment_count":1277747,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05933304","title":"A Study of the Effectiveness of Moderna COVID-19 Vaccine","phase":"","overall_status":"COMPLETED","enrollment_count":927004,"lead_sponsor_name":"ModernaTX, Inc.","has_results":false},{"nct_id":"NCT05321433","title":"Tobacco Use and the Risk of COVID-19 and Adverse Outcomes","phase":"","overall_status":"COMPLETED","enrollment_count":757585,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT04838795","title":"Sisonke (Together): OPEN LABEL TRIAL COVID-19","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":477102,"lead_sponsor_name":"Wits Health Consortium (Pty) Ltd","has_results":false},{"nct_id":"NCT06160128","title":"Clinical Outcomes and Pharmacotherapy Effectiveness in the VA Health Care System (COPE-VA)","phase":"","overall_status":"RECRUITING","enrollment_count":400000,"lead_sponsor_name":"VA Office of Research and Development","has_results":false},{"nct_id":"NCT05186571","title":"Myopericarditis After Messenger Ribonucleic Acid (mRNA) COVID-19 Vaccination in Children 5-11 Years Old","phase":"","overall_status":"UNKNOWN","enrollment_count":350000,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT03944447","title":"Outcomes Mandate National Integration With Cannabis as Medicine","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":200000,"lead_sponsor_name":"OMNI Medical Services, LLC","has_results":false},{"nct_id":"NCT04471701","title":"Italian Web-based Cross-sectional Survey on COVID-19","phase":"","overall_status":"COMPLETED","enrollment_count":200000,"lead_sponsor_name":"Institute of Biomedical Technologies-National Research Council, Italy","has_results":false},{"nct_id":"NCT04756609","title":"Systematic Offer of Nurse-Driven Screening for COVID-19 in Emergency Departments in the Paris Metropolitan Area, DEPIST-COVID","phase":"NA","overall_status":"COMPLETED","enrollment_count":138352,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT04351503","title":"A Systems Approach to Predict the Outcome of SARS-CoV-2 in the Population of a City; COVID-19","phase":"","overall_status":"COMPLETED","enrollment_count":126586,"lead_sponsor_name":"University Hospital, Basel, Switzerland","has_results":false},{"nct_id":"NCT05366322","title":"A Study to Compare mRNA-1273 Versus BNT162b2 COVID-19 Vaccines Among Immunocompromised Adults","phase":"","overall_status":"COMPLETED","enrollment_count":124879,"lead_sponsor_name":"ModernaTX, Inc.","has_results":false},{"nct_id":"NCT04392388","title":"Health, Perception, Practices, Relations and Social Inequalities in the General Population During the Covid-19 Crisis","phase":"","overall_status":"COMPLETED","enrollment_count":96883,"lead_sponsor_name":"Institut National de la Santé Et de la Recherche Médicale, France","has_results":false},{"nct_id":"NCT04944329","title":"Hip Fracture and COVID-19","phase":"","overall_status":"COMPLETED","enrollment_count":73661,"lead_sponsor_name":"Centre Hospitalier Universitaire de Nīmes","has_results":false},{"nct_id":"NCT05047900","title":"The Impact of SARS-CoV-2 Rapid Antigen Testing Kit Screening in Bangkok Community","phase":"NA","overall_status":"COMPLETED","enrollment_count":70000,"lead_sponsor_name":"Mahidol University","has_results":false},{"nct_id":"NCT04915781","title":"Tobacco Use and COVID-19 Incidence in the Finnish General Population","phase":"","overall_status":"COMPLETED","enrollment_count":60872,"lead_sponsor_name":"Finnish Institute for Health and Welfare","has_results":false},{"nct_id":"NCT04378452","title":"Assessment of the Psycho-social Impact of COVID-19 Outbreak","phase":"","overall_status":"COMPLETED","enrollment_count":56656,"lead_sponsor_name":"Fundació Institut Germans Trias i Pujol","has_results":false},{"nct_id":"NCT04664049","title":"The Outcomes of NRICM101 on SARS-COV-2 (COVID-19) Infection","phase":"","overall_status":"UNKNOWN","enrollment_count":51000,"lead_sponsor_name":"National Research Institute of Chinese Medicine, Ministry of Health and Welfare","has_results":false},{"nct_id":"NCT04368728","title":"Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":46969,"lead_sponsor_name":"BioNTech SE","has_results":true},{"nct_id":"NCT04652102","title":"A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":39680,"lead_sponsor_name":"CureVac","has_results":true},{"nct_id":"NCT04611802","title":"A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":33000,"lead_sponsor_name":"Novavax","has_results":false},{"nct_id":"NCT04516746","title":"Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":32450,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT04636697","title":"Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults","phase":"PHASE2, PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":30918,"lead_sponsor_name":"Medicago","has_results":false},{"nct_id":"NCT04470427","title":"A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":30415,"lead_sponsor_name":"ModernaTX, Inc.","has_results":true},{"nct_id":"NCT07266558","title":"A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":30000,"lead_sponsor_name":"ModernaTX, Inc.","has_results":false},{"nct_id":"NCT05059106","title":"EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF THE HALF DOSE OF THE VACCINE ChadOx1 nCoV-19 (AZD1222) for COVID-19","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":29637,"lead_sponsor_name":"Federal University of Espirito Santo","has_results":false},{"nct_id":"NCT04532411","title":"COVID-19 Testing Sample Acquisition Throughput and Efficiency","phase":"","overall_status":"COMPLETED","enrollment_count":28948,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT04847102","title":"A Phase III Clinical Study of a SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine Candidate Against COVID-19 in Population Aged 18 Years and Above","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":28000,"lead_sponsor_name":"Walvax Biotechnology Co., Ltd.","has_results":false},{"nct_id":"NCT04715607","title":"COVID-19: SARS-CoV-2 Detection in Saliva, Oropharyngeal and Nasopharyngeal Specimens","phase":"NA","overall_status":"COMPLETED","enrollment_count":27947,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT04401085","title":"COVID-19: Herd Immunity Study in the Czech Republic","phase":"","overall_status":"COMPLETED","enrollment_count":27000,"lead_sponsor_name":"Institute of Health Information and Statistics of the Czech Republic","has_results":false},{"nct_id":"NCT04411576","title":"Current and Past SARS-CoV-2 Infection and COVID-19 in Healthcare","phase":"","overall_status":"COMPLETED","enrollment_count":26326,"lead_sponsor_name":"Karolinska University Hospital","has_results":false},{"nct_id":"NCT04408014","title":"Seroepidemiological Study of SARS-CoV-2 (COVID-19) Infection in Population Subgroups in the State of São Paulo","phase":"","overall_status":"COMPLETED","enrollment_count":18901,"lead_sponsor_name":"Butantan Institute","has_results":false},{"nct_id":"NCT04955626","title":"To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":16372,"lead_sponsor_name":"BioNTech SE","has_results":true},{"nct_id":"NCT04583995","title":"A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":15185,"lead_sponsor_name":"Novavax","has_results":false},{"nct_id":"NCT05172024","title":"Understanding the Long-term Impact of COVID-19 in Adults (RECOVER)","phase":"","overall_status":"COMPLETED","enrollment_count":15172,"lead_sponsor_name":"NYU Langone Health","has_results":false},{"nct_id":"NCT05172011","title":"Understanding the Long-term Impact of COVID on Children and Families","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":15028,"lead_sponsor_name":"NYU Langone Health","has_results":false},{"nct_id":"NCT05168813","title":"Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":14237,"lead_sponsor_name":"COVID-19 Prevention Network","has_results":true},{"nct_id":"NCT05894590","title":"Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19","phase":"","overall_status":"COMPLETED","enrollment_count":13680,"lead_sponsor_name":"ModernaTX, Inc.","has_results":false},{"nct_id":"NCT05894499","title":"Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19","phase":"","overall_status":"COMPLETED","enrollment_count":13309,"lead_sponsor_name":"ModernaTX, Inc.","has_results":false},{"nct_id":"NCT04922788","title":"Study to Evaluate the Safety, Immunogenicity, and Efficacy of Nanocovax Vaccine Against COVID-19","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":13006,"lead_sponsor_name":"Nanogen Pharmaceutical Biotechnology Joint Stock Company","has_results":false},{"nct_id":"NCT05032976","title":"Korea Comirnaty Post-marketing Surveillance","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":12000,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT04407429","title":"Vienna Versus SARS-CoV-2 Virus Study","phase":"","overall_status":"UNKNOWN","enrollment_count":12000,"lead_sponsor_name":"Medical University of Vienna","has_results":false},{"nct_id":"NCT04385251","title":"International SARS-CoV-2 (COVID-19) Infection Observational Study","phase":"","overall_status":"COMPLETED","enrollment_count":11973,"lead_sponsor_name":"University of Minnesota","has_results":false},{"nct_id":"NCT04796896","title":"A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":11942,"lead_sponsor_name":"ModernaTX, Inc.","has_results":true},{"nct_id":"NCT04816643","title":"A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":11837,"lead_sponsor_name":"BioNTech SE","has_results":false},{"nct_id":"NCT04334954","title":"SARS-COV2 Pandemic Serosurvey and Blood Sampling","phase":"","overall_status":"COMPLETED","enrollment_count":11363,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}